Skip to main content

Diabetes

  • Lilly launches Humalog Junior KwikPen

    INDIANAPOLIS — Eli Lilly’s latest introduction is making half-unit doses of insulin easier for patients with Type 1 and Type 2 diabetes. The company on Wednesday launched its Humalog Junior KwikPen, which it said is the only prefilled, disposable half-unit insulin pen. The Food and Drug Administration approved the product in June to treat diabetes.

  • FDA approves Novo Nordisk’s Fiasp fast-acting insulin

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new fast-acting mealtime insulin from Novo Nordisk. The agency granted approval to Fiasp to treat adults with diabetes.

    The drug is a formulation featuring the company’s NovoLog insulin aspart developed with the aim of achieving properties that more closely match the natural physiological insulin mealtime response of someone without diabetes.

  • Thrifty White Pharmacy is improving patient outcomes through new diabetes pilot

    PLYMOUTH, Minn. — Thrifty White Pharmacy is making a significant difference in patient lives through its new diabetes care program, which places recipients into a medsync program replete with comprehensive medication therapy management sessions, patient disease management goal setting and follow through. Thrifty White also offers a compliance packaging service, HealthyPack Rx, that helps organize and manage a patient's medication.

  • BD intros 6-mm pen needle for injection pens

    FRANKLIN LAKES, N.J. — BD is bringing a new option for patients using pen injection devices. The BD Ultra-Fine micro pen needle 6 mm x 32 gauge is set for distribution in September, bringing a new needle length option to patients with diabetes who inject insulin.

  • Ascensia fosters product innovation through new Ascensia Diabetes Challenge

    LISBON, Portugal — Ascensia Diabetes Care on Wednesday announced the launch of the Ascensia Diabetes Challenge, a global innovation competition that is seeking innovative digital solutions to support diabetes management and improve the lives of those living with type 2 diabetes.

  • Study supports use of GlucoTrack, a non-invasive glucose monitoring device

  • Sanofi gets tentative FDA approval for Humalog follow-on Admelog

    SILVER SPRING, Md. — The Food and Drug Administration recently granted tentative approval to Sanofi’s Admelog (insulin lispro injection, 100 units/ml), a rapid-acting human insulin analog. The drug, a follow-on biologic version of Lilly’s Humalog, is indicated to improve glycemic control in patients with diabetes. 
     
    The approval means that Admelog has met all requirements for the regulatory agency, pending any patent issues that have not yet been resolved. 
     

  • Study: One Drop|Mobile diabetes management app helps reduce A1C

    NEW YORK — One Drop on Friday announced the results of a retrospective study of people with diabetes (type 1 and type 2) using the One Drop | Mobile diabetes management app, demonstrating a 1.1% to 1.3% absolute reduction in A1C in just four months.

    The results were published Thursday in JMIR Diabetes.

X
This ad will auto-close in 10 seconds